Skip to NavigationSkip to content


Syntimmune appoints Pfizer, AbbVie veteran as new CMO

Published on: 10/07/18

The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take the role of current CMO Dr Donald Johns who will become the Executive Vice President of Medical and Scientific Affairs for Syntimmune.

Having earned both an MD and PhD in neurosciences from John Hopkins University School of Medicine, Dr Saltarelli brings to the role a variety of expertise developed through experiences in discovery research, clinical development, pipeline strategy and global regulatory operations.

Top Ten most popular articles on this week

As the first week of July comes to an end we take a look over the most popular stories of the previous seven days.

While a series of scandals have drawn some of the big names into a web of legal issues, this week has offered a glimpse of hope as progress is made in innovative new treatments.

AbbVie ordered to pay $448m over generic delays

A US Judge has ordered pharmaceutical company AbbVie to pay $448 million after determining that the company had used sham litigation in an effort to delay generic versions of the testosterone replacement drug AndroGel from getting to market.

The ruling made in Philadelphia by US District Judge Harvey Bartle acted to conclude an anti-trust lawsuit first filed in 2014 by the Federal Trade Commission against AbbVie and its partner Besins Healthcare. The decision followed a non-jury trial in which the capabilities of the FTC were put to test.

Abbvie and Google's Calico extend age-related disease partnership to $2.5bn

The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development collaboration, originally signed in 2014, for another three years.

AbbVie/Roche gain FDA approval for blockbuster treatment

AbbVie and Roche have a chalked up a major success, after the FDA gave its approval for Venclexta, in combination with rituximab, for the treatment of patients with chronic lymphocytic leukaemia (CLL).

This regimen will be available on a second-line basis and will be the first oral-based, chemotherapy-free treatment for CLL.

The treatment is tipped to become a blockbuster earner for the companies, with peak sales estimates of between $2.5 billion to $3 billion.

Top Ten most popular articles on this week

It's Friday the 13th, but that doesn't change a strong showing from the industry this week as it continued to deliver some remarkable news: the pharma M&A train keeps rolling as the year goes on as Novartis announced it is to shell out $8.7 billion to snatch up gene therapy biotech AveXis, while an exciting partnership is promising to transform the hepatitis C market by offering a drug which boasts a 97% cure rate in trials for as little as $300.

New hepatitis C combo boasts 97% cure rate for just $300

Image Credit: BruceBlaus

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working to bring a new, effective and affordable combination therapy to patients with hepatitis C (HCV).

AbbVie's rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3

AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own best-selling blockbuster Humira (adalimumab) at Phase 3 in the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to methotrexate, hitting both its primary and secondary endpoints.

Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie which grants patent licenses for the sale of the product in Europe and the US, and stipulates that the three parties agree to dismiss any ongoing litigation surrounding the issue.

Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack

Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of the company’s testosterone replacement drug AndroGel drove him to a heart attack, a risk which he argues was vastly misrepresented.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches